Using plural phages to treat Multiple Drug Resistant (MDR) Acinetobacter baumannii
Acinetobacter baumannii (AB) is one of the important multiple drug
resistant (MDR) bacterial infection with environmental contamination
especially in hospitals. AB is the major fatal cause of acquired hospital
bacterial infection. With the limitation to develop new antibiotic drug,
nowadays, phage therapy is reignited as an alternative strategy to fight
against MDR bacterium. One of the main problems concerning phage
therapy is that bacterium can develop to be a lysogen which becomes
resistant to the same phage treatment. This lysogenic mechanism
is regulated when bacterium host is infected by temperate phage
which unfortunately seems to be the major kind of isolated phages
by various researchers. It is seldom to isolate virulent phage which
can keep re-infecting the bacterial host by the phage’s progeny without
lysogenic pathway. Using the proper amounts of temperate phage, so
called multiplicity of infection (MOI), to infect the bacterial hosts can
theoretically prevent lysogenic pathway. However, it is not practical
to perfectly prepare the proper amount of MOI for the treatment. In
this study, many isolated ABs have been obtained from patients. The
AB 116 and AB 160 are used as the models to study their susceptibility
to phage therapy. Plural kinds of AB-phages (bacteriophages of AB)
for each particular AB have also been isolated and called AB-phage a,
b, c and d. AB-phage a and c can infect AB 116 while AB 160 can be
infected by AB-phage a, b and d. In this presentation, using plural ABphage
to treat AB in vitro will be presented and discussed.